Watson resubmits Oxytrol NDA
Executive Summary
Watson resubmits Oxytrol (oxybutynin) NDA for treatment of overactive bladder with Phase IIIb trial data. FDA issued "not approvable" letter for Oxytrol in March (1"The Pink Sheet" April 1, p. 24). Agency decision is due by Feb. 28...